Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Clinical trial enrollment has long been a bottleneck in drug development
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
The Phase-2b study is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA
The investigational therapy uses SteadyTeq, a proprietary copolymer technology from Medincell designed to release olanzapine steadily over time
Soficitinib is a potent and selective TYK2 inhibitor under development for multiple T-cell mediated autoimmune disorders
Nitrosamines have prompted evolving global guidelines that demand rigorous industry oversight
Indian companies must make their own intermediates and support small industries: Dr. K. Nagaiah, Chief Scientist, CSIR - IICT, Hyderabad
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
Subscribe To Our Newsletter & Stay Updated